Breast Cancer New Indication: Sacituzumab Govitecan for HR+, her2 Negative Breast Cancer Ulas D. Bayraktar, MD 2023-03-15
Colorectal Cancer New Indication: Encorafenib, Binimetinib, and Cetuximab for bRAF V600E Mutant Colorectal Cancer Ulas D. Bayraktar, MD 2023-03-15
Waldenstrom macroglobulinemia New Reference: Bortezomib, Rituximab, Cyclophosphamide for Waldenstrom Ulas D. Bayraktar, MD 2023-03-15
Hepatocellular Carcinoma New Protocol: Tremelimumab and Durvalumab for HCC Ulas D. Bayraktar, MD 2023-01-10
Follicular Lymphoma New Drug: Mosunetuzumab for R/R Follicular Lymphoma Ulas D. Bayraktar, MD 2023-01-10
Non-Small Cell Lung Cancer New Protocol: Cemiplimab with Chemotherapy in NSCLC Ulas D. Bayraktar, MD 2023-01-10
Non-Small Cell Lung Cancer New Indication: Durvalumab with Tremelimumab in Metastatic NSCLC Ulas D. Bayraktar, MD 2023-01-10
